Plasma risperidone levels and clinical response in patients with first-episode psychosis [2]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 6, 2005, Pages 609-611

  Verma, Swapna K ^a   Chay, Hoon Tan ^b   Yiong, Huak Chan ^b   Siow, Ann Chong ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; PALIPERIDONE; RISPERIDONE;

ADULT; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 27944456051     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000186242.26050.1e     Document Type: Letter

References (12)

1. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-268.
2. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999;60(7):469-476.
3. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology. 2001;153:238-243.
4. Aravagiri M, Marder SR, Nuechterlein KH, et al. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003;25:657-664.
5. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology. 1995;122:11-19.
6. Anderson C, True J, Ereshefsky L, et al. Risperidone clinical efficacy: role of metabolite 9-hydroxy-risperidone. Psychopharmacol Bull. 1994;30:88.
7. Darby JK, Pasta DJ, Elfand L, et al. Risperidone dose and blood variability: accumulation effects and interindividual and intra-individual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol. 1997;17:478-484.
8. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM IV Axis I Disorders, Patient Edition (SCID-P), Version 2. New York: New York State Psychiatric Institute, Biometrics Research; 1994.
9. Kay S, Fiszbein R, Opler A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
10. Simpson GM, Angus JWS. Drug induced extrapyramidal disorders: a rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
11. Remmerie BM, Sips LL, De Vries R, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;783:461-472.
12. Halliday J, Farrington S, Macdonald S, et al. Nithsdale schizophrenia surveys 23: movement disorders: 20 year review. Br J Psychiatry. 2002;181:422-427.